Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
April 12 2018 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma and other diseases of the eye,
today announced the appointment of Scott Laranjo as Director,
Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice
President of Marketing. Mr. Laranjo will direct future marketing
activities associated with RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%, a fixed dose combination of
Aerie product Rhopressa®, and widely prescribed PGA latanoprost.
The RoclatanTM new drug application (NDA) submission to the U.S.
Food and Drug Administration (FDA) is expected to take place in the
second quarter of 2018. Mr. Laranjo previously held related
marketing positions at UCB, Inc. and Allergan, Inc.
In connection with his acceptance of the position as Director,
Marketing, RoclatanTM, Mr. Laranjo will receive awards totaling
14,400 stock options that will vest over 4 years, with 25% vesting
on the first anniversary of the hire date and the remainder vesting
ratably on each of the subsequent 36 monthly anniversaries of the
hire date. This award was made outside of Aerie’s
stockholder-approved equity incentive plan and was approved by the
Company’s independent directors as an inducement material to Mr.
Laranjo entering into employment with the Company in reliance on
NASDAQ Listing Rule 5635(c)(4), which requires this public
announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma
and other diseases of the eye. Aerie's first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension, was approved by the U.S. Food and
Drug Administration (FDA) in December 2017. A link to the full
product label is available on the Aerie website at
http://investors.aeriepharma.com. Aerie’s second product candidate,
RoclatanTM (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dose combination of Rhopressa® and
widely prescribed PGA latanoprost, achieved its primary efficacy
endpoint in two Phase 3 registration trials, named Mercury 1 and
Mercury 2, and also achieved successful 12-month safety and
efficacy results in Mercury 1. The RoclatanTM NDA submission is
expected to take place in the second quarter of 2018. Aerie is also
focused on global expansion and the development of additional
product candidates and technologies in ophthalmology.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercial launch and potential future sales of
Rhopressa® and RoclatanTM and any future product candidates, if
approved; our commercialization, marketing, manufacturing and
supply management capabilities and strategies; third-party payer
coverage and reimbursement of Rhopressa® and RoclatanTM and any
future product candidates, if approved; the glaucoma patient market
size and the rate and degree of market adoption of Rhopressa® and
RoclatanTM and any future product candidates, if approved, by
eye-care professionals and patients; the timing cost or other
aspects of the commercial launch of Rhopressa® and RoclatanTM and
any future product candidates, if approved; the success, timing and
cost of our ongoing and anticipated preclinical studies and
clinical trials for Rhopressa®, with respect to regulatory approval
outside the United States, and RoclatanTM and any future product
candidates, including statements regarding the timing of initiation
and completion of the studies and trials; our expectations
regarding the effectiveness of Rhopressa®, RoclatanTM and any
future product candidates and results of our clinical trials and
any potential preclinical studies; the timing of and our ability to
request, obtain and maintain FDA or other regulatory authority
approval of, or other action with respect to, as applicable,
Rhopressa®, RoclatanTM and any future product candidates in the
United States, Canada, Europe, Japan and elsewhere, including the
expected timing of, and regulatory and/or other review of, filings
for, as applicable, Rhopressa®, RoclatanTM and any future product
candidates; the potential advantages of Rhopressa®, RoclatanTM and
any future product candidates; our plans to pursue development of
additional product candidates and technologies in ophthalmology,
including development of Rhopressa® and RoclatanTM for additional
indications, our preclinical retina programs and other therapeutic
opportunities; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma and ophthalmology; our
ability to protect our proprietary technology and enforce our
intellectual property rights; and our expectations regarding
collaborations, licensing, acquisitions and strategic operations,
including our ability to in-license or acquire additional
ophthalmic products, product candidates or technologies. By their
nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics, industry
change and other factors beyond our control, and depend on
regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, FDA approval of
Rhopressa® does not constitute FDA approval of RoclatanTM, and
there can be no assurance that we will receive FDA approval for
RoclatanTM or any future product candidates. FDA approval of
Rhopressa® also does not constitute regulatory approval of
Rhopressa® in jurisdictions outside the United States, and there
can be no assurance that Rhopressa® will obtain regulatory approval
in other jurisdictions. Forward-looking statements are not
guarantees of future performance and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180412005070/en/
Aerie PharmaceuticalsMedia:Tad
Heitmann, 949-526-8747theitmann@aeriepharma.comorInvestors:Richard
Rubino, 908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on behalf of Aerie
PharmaceuticalsMedia:Justin Jackson,
212-213-0006jjackson@burnsmc.comorInvestors:Ami Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024